Abstract: A method of treating a disease or condition comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage comprising a therapeutically effective amount of a drug to treat said disease or condition and a form of hyaluronic acid characterized in that the composition is immediately available to transport the drug percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of the disease or condition to be treated.

Abstract: A process is provided for the preparation of 1,2,5,6-tetrahydro-3-carboalkoxypyridines of formula (III) ##STR1## wherein R is a straight or cyclic substituted or unsubstituted alkyl chain having 1 to 6 carbon atoms, phenyl C.sub.1-6 alkyl, menthol or a derivative of menthol, or a derivative of camphor, and R' is an alkyl chain having 1 to 4 carbon atoms or phenyl C.sub.1-6 alkyl comprising reacting an alkyl pyridinium salt of formula ##STR2## wherein R and R' are as defined above and X is a suitable leaving group with sodium triacetoxyborohydride in the presence of an acid.

Abstract: A valve assembly is provided including a housing having an opening wherein a cartridge is inserted. The housing has axially aligned inlets and outlets for hot and cold water. The cartridge includes a stationary sleeve containing a rotatable stem member. The stem member carries a compound seal having a first primary sealing portion for sealing the inlet of the stationary sleeve and a secondary seal portion for separating first and second chamber areas of the stem member. Preferably the outlets of said moveable stem and said stationary sleeve are substantially L-shaped, and inverted L-shaped respectively, which are selectively alignable to provide for an increased volume of water through the valve assembly. The housing includes a dividing dam in the outlet splitting the outlet in two.

Abstract: A loading dock bumper comprising:(a) a first rigid part for fastening to said dock(b) a second rigid part engaged with said first rigid part by at least one connecting device, said second rigid part being moveable with respect to said first rigid part between a first and a second position, and said first and said second rigid parts when engaged defining a substantially enclosed hollow therebetween; and(c) a compressible resilient material dispersed between said first and second rigid parts within the hollow therebetween,wherein said second part is moveable with respect to the first part between the first position wherein the resilient material is not compressed and the second position wherein said resilient material is compressed, wherein any load applied to said bumper moves the second part towards the second position and compresses the resilient material to provide dampening of the load applied.

Abstract: A process is provided for the preparation of compounds of formula I, ##STR1## useful in the preparation of compounds such as Omeprazole, Lansoprazole and Pantoprazole, wherein R.sup.1 =H or CH.sub.3, R.sup.2 =H or CH.sub.3, R.sup.3 =Alkoxy (1-4C), OCH.sub.2 CF.sub.3, Cyano, Hydrogen, Halogen, Acetoxy or Aryloxy, any electron withdrawing group or salts (organic or inorganic) of electron donating groups, R=Alkoxy, Hydroxy, Halogen, Activated ester, Tosylate, Mesylate, Thiol or Xanthyl, wherein the process for the preparation of compound of formula I employs a free radical reaction to functionalize the 2-position.

Abstract: A cartridge for a valve housing having outlets, the cartridge comprising a stationary body sleeve for fixed insertion within the housing and having outlet ports permanently aligned with the outlets of the housing, a moveable substantially hollow stem sleeve inserted within the stationary body sleeve and having an opening selectively alignable with the ports of the stationary body sleeve, the body sleeve and hollow stem being connected to one another by a retaining ring which aligns and maintains the cartridge as a unit in the housing. The diverting valve may be installed as a deck mounted fixture in a tub, whirlpool, soaking bath, spa, roman tub, or the like wherein the tub spout is located below the flood line rim of the respective fixture wherein the diverting valve can be repaired by replacing the cartridge from the top of the valve by removing the handle and replacing the cartridge in its entirety.

Abstract: A process is provided for the manufacture of 4-lower-alkyl-5-hydroxymethyl-imidazole comprising reacting (4)-lower-alkyl imidazole with formaldehyde in an alkanol solvent having from 2 to 5 carbon atoms in the presence of a solid mild base suspended in the solvent.

Abstract: A method of accumulating a drug and a form of hyaluronic acid in the skin and/or exposed tissue of a human includes topically administering a therapeutically effective dosage amount of a formulation which comprises at least 5 mg/cm.sup.2 of the form of hyaluronic acid and a therapeutically effective amount of the drug.

Abstract: A winch assembly is provided including a single mounting bracket for mounting the winch assembly directly to a frame (for example beams) of a vehicle having a front and rear. The mounting bracket has a winch mounting area provided therewith, and a tire carrier and cooperative flexible member outlet area spaced from the winch mounting area towards the front of the vehicle. The mounting bracket is adapted to bolt directly to the frame members (for example beams) of a vehicle. The mounting bracket for the winch therefore obviates the need to provide welded or fastened reinforcing plates with the vehicle proximate the locations wherein the winch assembly is to be mounted.

Abstract: Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.

Abstract: A peritoneal dialysis solution consisting essentially of an effective amount of N-acetylglucosamine and electrolytes.

Abstract: Novel methods for the synthesis of substituted ureas and guanidines including Terazosin, Prazosin, Doxazosin, Tiodazosin, Trimazosin, Quinasin and Bunazosin (exemplary of 2-amino substituted Quinazolines), Meobentine and Bethanidine and novel intermediates suitable for use in such methods of synthesis are taught.

Abstract: A pharmaceutical composition is provided comprising:(1) an agent selected from a medicinal agent and a therapeutic agent and combinations thereof in a therapeutically effective amount to treat a disease or condition in humans who will benefit from the treatment with the agent; and(2) hyaluronic acid and/or pharmaceutically acceptable salts thereof and/or fragments, and subunits of hyaluronic acid, characterized in that said composition(a) is in a dosage form which is suitable for administration in humans; and(b) is in a form in which (i) component (1) is in an effective dosage amount to treat said disease or condition by penetration at the site to be treated; and (ii) component (2) is immediately available to transport component (1) at the site to be treated, and which component (2) is in an effective non-toxic amount to facilitate the transport of component (1) upon administration, through the tissue including scar tissue, at the site to be treated and through the cell membranes or the individual cells to be

Abstract: A combination for administration to a mammal which combination employes a therapeutically effective amount of medicinal and/or therepeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scarr tissue) at the site to be treated, through the cell membrane into the individual cells to be treated.

Abstract: A method is provided of inhibiting the narrowing of the vascular tubular walls of an animal by the proliferation of endothelial cells in the area of trauma after the vascular tubular walls have been traumatized, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof to the animal to inhibit the narrowing of the vascular tubular walls by the proliferation of endothelial cells into the area of trauma.

Abstract: A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of hyaluronic acid or salts thereof or homologues, analogues, derivatives, complexes, esters, fragments, or sub-units of hyaluronic acid to transport the drug to the site of the pathology or trauma of the disease or condition.

Abstract: The invention relates to a method of controlling the unloading of a drug from the skin or exposed tissue of a human into the lymphatic system comprising transporting an effective dosage amount of the drug into the skin or exposed tissue by an effective non-toxic amount of a form of hyaluronic acid.

Abstract: This invention relates to a method of inhibiting the narrowing of the tubular walls of an animal with a form of hyaluronic acid.

Abstract: A method of detoxifying a patient by peritoneal dialysis which patient will benefit from peritoneal dialysis treatment by involving underperfused or pathological tissue the administration of an agent suitable for peritoneal dialysis treatment, comprising administering to the patient a therapeutically effective dosage amount of a pharmaceutical composition for peritoneal dialysis treatment, each dosage amount comprising a therapeutically effective amount of an agent suitable for use in peritoneal dialysis and a sufficient amount of a form of hyaluronic acid selected from hyaluronic acid and non-toxic salts and combinations thereof sufficient to alter the agent's performance in the human body wherein said amount of the form of hyaluronic acid is sufficient to provide a dosage between 10 mg and 3000 mg of the form of hyaluronic acid and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons but greater than 150,000 daltons.

Abstract: A dosage amount of a pharmaceutical composition comprising a therapeutically effective amount of an agent to treat a disease or condition involving underperfused tissue and pathological tissue in humans and a form of hyaluronic acid, wherein the form of hyaluronic acid is available to transport the agent from the point of administration to the site to be treated.